Biotechnology
GC Biopharma's Study on Hunterase Lysosomal Delivery Mechanism Published in SCIE-Indexed Journal
YONGIN, South Korea, Aug. 21, 2025 /PRNewswire/ -- GC Biopharma, a leading global pharmaceutical company based inSouth Korea, announced today that it has revealed the delivery mechanism of Hunterase (idursulfase beta), a recombinant enzyme replacement therapy for Hunter syndrome (MPS II). The res...
2025-08-21 13:00
1581
Debut of new form of health supplement product! WCC biomedical collaborate with Synmosa toward the niche market!
TAIPEI, Aug. 21, 2025 /PRNewswire/ -- WCC Biomedical
2025-08-21 09:23
1674
Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth
MELBOURNE, Australia and INDIANAPOLIS, Aug. 21, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the half-year ended30 June 2025. All figures are in USD unless stated otherwise. H1 2025 key results[1] Group performan...
2025-08-21 08:23
2716
Cell therapy is promising in treating psychiatric disorders, such as depression. -- A proof-of-principle study published in "Cell Stem Cell" by the laboratory of Dr. Chen, founder of UniXell Biotech, suggests this.
SHANGHAI, Aug. 20, 2025 /PRNewswire/ -- On August 11, 2025, the research team led by Professor Yuejun Chen, founder of UniXell Biotech, published an article titled "Human stem cell-derived A10 dopaminergic neurons specifically integrate into mouse circuits and improve depression-like behaviors" i...
2025-08-20 20:49
2309
Mabwell's CDH17-targeting ADC 7MW4911 Receives IND Clearance from FDA
SHANGHAI, Aug. 19, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D code: 7MW4911) received INDclearance from the U.S. Food and Drug Administration (FDA). The clearance enables ...
2025-08-19 22:00
1804
WuXi Biologics Reports Solid 2025 Interim Results
* Revenue increased by 16.1% YoY to RMB 9,953.2 million; revenue growth from continuing operations was 20.2% * IFRS Gross profit margin expanded by 3.6% YoY to 42.7% * EBITDA grew 50.5% YoY and IFRS net profit increased 54.8% YoY * Adjusted EBITDA grew 20.6% YoY and adjusted net profit incr...
2025-08-19 20:35
2289
Nature Medicine Publishes Results of Phase II Study of Sacituzumab Tirumotecan Plus Tagitanlimab as First-Line Therapy for NSCLC
CHENGDU, China, Aug. 19, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990) announced that clinical data from a Phase II study evaluating novel TROP2 antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) in combination with PD-L1 monocl...
2025-08-19 20:09
1697
Nilesh Shah joins Illumina as Head of Region, AMEA
SINGAPORE, Aug. 19, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global
leader in DNA sequencing and array-based technologies, announced today the
appointment ofNilesh Shah as Head of Region, AMEA, effective immediately.
2025-08-19 14:14
2066
Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma
SHANGHAI and HONG KONG, Aug. 19, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic ma...
2025-08-19 13:26
1858
Beyfortus® (nirsevimab) approved in Singapore to protect all infants against RSV disease
* Beyfortus (nirsevimab) is the only option that can offer RSV protection designed for all infants with proven high, sustained efficacy, favourable safety and public health impact demonstrated in the real world.[1] * In the recent HARMONIE trial findings, Beyfortus reduced RSV hospitalisation...
2025-08-19 11:00
2617
RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries
YANTAI, China, Aug. 19, 2025 /PRNewswire/ -- RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceutical (China) Co., Ltd. ("Santen China"), a wholly-owned subsidiary o...
2025-08-19 08:00
2061
Avixgen, a subsidiary of Dx&Vx, signs a licensing-out agreement worth USD 360 million with a U.S. biotech company for its next-generation drug delivery platform (ACP).
* This innovative platform technology, with exceptional scalability, has been recognized as highly valuable even with limited rights granted. * DXVX is taking the lead in business development, with several companies in the due diligence stage, and additional deals are anticipated. SEOUL, South...
2025-08-18 21:00
1925
LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company
BEIJING, Aug. 18, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious d...
2025-08-18 20:00
2750
KELUN-BIOTECH ANNOUNCES 2025 INTERIM RESULTS
* Revenue reached approximately RMB950.4 million, with total commercial sales RMB309.8million, representing a significant increase in proportion * Research and development expenses was approximately RMB611.5 million * Loss for the period was RMB145.2 million; adjusted loss for the period[1] ...
2025-08-18 18:29
2421
GC Biopharma Signs MOU with Thai Red Cross Society to Strengthen Collaboration on Plasma-Derived Therapies
YONGIN, South Korea, Aug. 18, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced today that it has signed a Memorandum of Understanding (MOU) with the Thai Red Cross Society (TRCS) to cooperate on workforce training for the production of plasma-deri...
2025-08-18 12:40
1696
Ascletis Announces the Combination of ASC47 and ASC31, its Dual GLP-1R/GIPR Peptide Agonist, Demonstrated Significantly Greater Weight Loss Compared to the Combination of ASC47 and Tirzepatide in an Animal Model of Obesity
- Combination of a low dose of ASC47 with ASC31, a novel peptide agonist targeting bothGLP-1 receptor (GLP-1R) and GIP receptor (GIPR), resulted in a 44.8% reduction in body weight after 14 days of treatment in a diet-induced obese (DIO) mouse model. - Combination of a low dose of ASC47 with A...
2025-08-18 08:15
1839
GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation
Rising Global Footprint, Best-in-Class Innovation, and ESG Excellence Set Stage for Sustained Value Creation PISCATAWAY, N.J., Aug. 17, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a global pioneer in life sciences innovation, today announced outstanding interim results for the ...
2025-08-17 20:01
2385
Novel Gene Therapy for ALS cleared for global trials in China and the U.S.
BEIJING, Aug. 15, 2025 /PRNewswire/ -- SineuGene Therapeutics Co., Ltd. ("SineuGene"), clinical-stage biotechnology company that mainly focuses on gene therapies for neurological disorders, announced today thatChina's National Medical Products Administration (NMPA) has cleared the Investigational...
2025-08-15 19:00
1843
CARsgen Therapeutics Announces 2025 Interim Results
SHANGHAI, Aug. 14, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2025 Interim Results. Business Highlights * Cash and bank balances were around RMB1,261 million as of June 30,...
2025-08-15 08:15
2955
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY® by the Taiwan Food and Drug Administration for the Treatment of Moderately to Severely Active Ulcerative Colitis
SHANGHAI, Aug. 14, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the Taiwan Food and Drug Adminis...
2025-08-14 12:02
2214
Week's Top Stories
Most Reposted
AI adoption is widespread, but developer confidence is still catching up, Agoda report finds
[Picked up by 315 media titles]
2026-02-03 11:00
Mastercard Launches Portfolio of Fleet Solutions in Asia Pacific
[Picked up by 311 media titles]
2026-02-04 09:00Colebrook Bosson Saunders Officially Launches Lana, A Circular Ergonomic Laptop Stand for the Hybrid Generation
[Picked up by 305 media titles]
2026-02-03 12:00
Rockwell Automation Strengthens Industrial Cybersecurity with New Security Operations Center in Singapore
[Picked up by 298 media titles]
2026-02-09 10:00
AIA RESEARCH REVEALS INGRAINED HEALTH STEREOTYPES ARE HOLDING BACK WELLBEING IN ASIA
[Picked up by 287 media titles]
2026-02-09 16:08
